At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 92 enrolled
Drug / intervention
QBW251 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double Blind, Placebo Controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of Multiple Doses of QBW251 in Patients With COPD
In Brief
A Phase 2 clinical trial evaluating QBW251 and Placebo for Chronic Obstructive Pulmonary Disease, COPD. Completed, enrolled 92 participants across 16 sites in 2 countries.
Detailed Summary
To evaluate the efficacy, safety and tolerability of multiple doses of QBW251 vs placebo administered orally, on airway function, lung volume, and quality of life in patients with chronic obstructive pulmonary disease (COPD)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesPoland, United States
Collaborators--
Timeline
Phase 2CompletedFinished
20162017201820192020202120222023202420252026
Enrollment StartApr 2015
First PostedMay 2015
Primary CompletionDec 2016
Study CompletionJan 2017
TodayJul 2026
First PostedMay 20, 2015
Enrollment StartApr 30, 2015
Primary CompletionDec 27, 2016
Study CompletionJan 23, 2017
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 11.1 years ago
Interventions
QBW251drug
QBW251 capsule(s) taken orally twice per day
Placebodrug
Matching placebo capsule(s) taken orally twice per day